Ascentage Pharma Group International (AAPG) Key Metrics
AAPG key metrics, 2016–2025
Fiscal year ended December 31, 2025 · Chinese yuanAAPG returns How much profit the business earns on the capital it uses.
AAPG financial health Debt, liquidity and how easily interest is covered.
AAPG efficiency & capital use Working capital cycle and where the cash goes.
AAPG returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
AAPG debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
AAPG cash returned to shareholders
AAPG key metrics in Chinese yuan
2016–2025| 2025 | 2024 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|
| Returns & profitability | ||||||
| Return on equity (ROE) | −152.1% | −153.5% | — | — | — | — |
| Return on invested capital (ROIC) | −121.7% | −42.0% | — | — | — | — |
| Return on assets (ROA) | −36.7% | −15.5% | −121.6% | −38.1% | −20.2% | −18.2% |
| Return on tangible assets | −31.2% | −16.1% | −137.6% | −31.5% | −24.9% | −22.4% |
| Free cash flow margin | −215.2% | −13.8% | — | — | — | −642.5% |
| Financial health | ||||||
| Total debt | CN¥1.98B | CN¥1.67B | CN¥101.4M | CN¥42.0M | CN¥4.9M | CN¥830,000 |
| Cash & short-term investments | CN¥2.47B | CN¥1.24B | CN¥878.5M | CN¥971.5M | CN¥399.0M | CN¥451.9M |
| Net debt | −CN¥490.7M | CN¥431.9M | −CN¥777.1M | −CN¥929.4M | −CN¥394.1M | −CN¥451.1M |
| Debt / equity | 1.49 | 6.32 | 0.11 | — | — | — |
| Debt / assets | 0.50 | 0.64 | 0.08 | 0.03 | 0.01 | 0.00 |
| Current ratio | 1.79 | 1.26 | 4.50 | 9.41 | 5.21 | 5.97 |
| Quick ratio | 1.77 | 1.26 | 4.50 | 9.41 | 5.21 | 5.97 |
| Interest coverage | -22.4 | -5.7 | -136.3 | -9.4 | -2.3 | -35.2 |
| Working capital | CN¥1.30B | CN¥307.6M | CN¥707.0M | CN¥885.0M | CN¥335.2M | CN¥386.1M |
| Invested capital | CN¥834.6M | CN¥696.1M | CN¥113.4M | −CN¥1.94B | −CN¥525.9M | −CN¥465.7M |
| Tangible asset value | CN¥1.24B | CN¥173.5M | CN¥761.5M | −CN¥1.14B | −CN¥237.2M | −CN¥126.4M |
| Net current asset value | CN¥315.0M | −CN¥869.5M | CN¥594.5M | −CN¥1.25B | −CN¥298.7M | −CN¥144.2M |
| Capital allocation | ||||||
| Dividends paid | CN¥0 | CN¥0 | — | — | — | — |
| Share buybacks (net) | CN¥9.0M | CN¥0 | — | — | — | — |
| Capex / revenue | 4.9% | 2.5% | 561.0% | 726.6% | 324.5% | 44.0% |
| Capex / depreciation | 0.32 | 0.26 | 21.28 | 2.68 | 1.64 | 20.51 |
| Stock-based compensation / revenue | 3.7% | 2.1% | 488.0% | 405.1% | — | 847.7% |
| R&D / revenue | 194.0% | 96.6% | 3,196.3% | 3,666.3% | 1,877.6% | 1,339.4% |
| SG&A / revenue | 107.4% | 39.1% | 681.1% | 1,318.0% | 211.8% | 231.0% |
| Efficiency | ||||||
| Days sales outstanding | 115.1 | 36.9 | 97.8 | 351.4 | 466.1 | 395.5 |
| Days of inventory on hand | 48.8 | 82.8 | — | — | — | — |
| Days payables outstanding | 275.4 | 1,154.1 | 1,581.6 | — | — | 218.2 |
| Cash conversion cycle (days) | -111.5 | -1,034.5 | -1,483.8 | — | — | 177.4 |
| Receivables turnover | 3.17 | 9.90 | 3.73 | 1.04 | 0.78 | 0.92 |
| Payables turnover | 1.33 | 0.32 | 0.23 | 0.00 | 0.00 | 1.67 |
| Inventory turnover | 7.48 | 4.41 | — | — | — | — |
| Asset turnover | 0.17 | 0.37 | 0.01 | 0.01 | 0.01 | 0.01 |
| Average receivables | CN¥176.1M | CN¥99.1M | CN¥3.9M | CN¥6.6M | CN¥8.1M | CN¥8.3M |
| Average payables | CN¥99.4M | CN¥92.0M | CN¥9.1M | CN¥4.5M | CN¥2.0M | CN¥156,000 |
| Average inventory | CN¥17.6M | CN¥6.6M | — | — | — | — |
| Intangibles / total assets | 2.3% | 3.8% | 10.7% | 10.8% | 18.1% | 18.8% |
Computed from AAPG's annual financial statements (latest annual report filed April 29, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in Chinese yuan; data from EODHD. Averages use the opening and closing balance of each year.
AAPG valuation and financial ratios
Ascentage Pharma Group International earned a return on equity of −152.1% and a return on invested capital of −121.7% in fiscal 2025. It ended the year with CN¥2.0 billion of debt and CN¥2.5 billion in cash and short-term investments, a net cash position of CN¥490.7 million. It returned CN¥9.0 million to shareholders: CN¥0 in dividends and CN¥9.0 million in share buybacks.
See the AAPG income statement, the AAPG chart for price history, or the AAPG stock overview for the latest quote and news.
AAPG key metrics FAQ
What is Ascentage Pharma Group International's return on equity?
Ascentage Pharma Group International's return on equity (ROE) was −152.1% in fiscal 2025: net income of -CN¥1.2 billion on average shareholders' equity of CN¥794.7 million.
What is Ascentage Pharma Group International's ROIC?
Ascentage Pharma Group International's return on invested capital was −121.7% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Ascentage Pharma Group International have?
Ascentage Pharma Group International had total debt of CN¥2.0 billion at the end of fiscal 2025, a debt-to-equity ratio of 1.49 and more cash than debt.
Does Ascentage Pharma Group International pay a dividend?
Ascentage Pharma Group International did not pay a dividend in fiscal 2025.
Does Ascentage Pharma Group International buy back its shares?
Yes. Ascentage Pharma Group International spent CN¥9.0 million on net share repurchases in fiscal 2025.
What is Ascentage Pharma Group International's current ratio?
Ascentage Pharma Group International's current ratio was 1.79 at the end of fiscal 2025: current assets were 1.79 times current liabilities.